← Back to Screener
Rallybio Corporation Common Stock (RLYB)
Price$8.33
Favorite Metrics
Price vs S&P 500 (26W)75.62%
Price vs S&P 500 (4W)-17.36%
Market Capitalization$43.80M
All Metrics
Book Value / Share (Quarterly)$10.97
P/TBV (Annual)0.54x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-5.64
Price vs S&P 500 (YTD)48.18%
Net Profit Margin (TTM)-1046.39%
EPS (TTM)$-1.60
10-Day Avg Trading Volume0.07M
EPS Excl Extra (TTM)$-1.60
EPS (Annual)$-1.59
ROI (Annual)-15.49%
Cash / Share (Quarterly)$10.36
Revenue Growth QoQ (YoY)484.21%
ROA (Last FY)-14.42%
EBITD / Share (TTM)$-1.97
ROE (5Y Avg)-49.11%
Operating Margin (TTM)-3955.48%
Cash Flow / Share (Annual)$-5.64
P/B Ratio0.76x
P/B Ratio (Quarterly)0.50x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)14.48x
ROA (TTM)-15.03%
EPS Incl Extra (Annual)$-1.59
Current Ratio (Annual)14.50x
Quick Ratio (Quarterly)13.56x
3-Month Avg Trading Volume0.10M
52-Week Price Return283.33%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$3.27
P/S Ratio (Annual)51.05x
Asset Turnover (Annual)0.01x
52-Week High$11.49
EPS Excl Extra (Annual)$-1.59
26-Week Price Return79.61%
Quick Ratio (Annual)13.56x
13-Week Price Return42.51%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)14.50x
Enterprise Value$12.425
Asset Turnover (TTM)0.01x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-1046.39%
Cash / Share (Annual)$10.36
3-Month Return Std Dev116.64%
Net Income / Employee (TTM)$-1
ROE (Last FY)-15.49%
EPS Basic Excl Extra (Annual)$-1.59
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.60
ROI (TTM)-16.25%
P/S Ratio (TTM)51.05x
Revenue / Share (Annual)$0.15
Tangible BV / Share (Annual)$4.47
Price vs S&P 500 (52W)253.50%
Year-to-Date Return50.82%
5-Day Price Return0.85%
EPS Normalized (Annual)$-1.59
ROA (5Y Avg)-45.30%
Net Profit Margin (Annual)-1046.39%
Month-to-Date Return-7.69%
Cash Flow / Share (TTM)$-1.80
EBITD / Share (Annual)$-1.97
Operating Margin (Annual)-3955.48%
ROI (5Y Avg)-49.11%
EPS Basic Excl Extra (TTM)$-1.60
P/TBV (Quarterly)0.75x
P/B Ratio (Annual)0.50x
Pretax Margin (TTM)-1046.39%
Book Value / Share (Annual)$10.97
Price vs S&P 500 (13W)41.83%
Beta-1.16x
Revenue / Share (TTM)$0.15
ROE (TTM)-16.25%
52-Week Low$1.79
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.80
3.80
3.80
2.29
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
RLYBRallybio Corporation Common Stock | 51.05x | — | — | — | $8.33 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Rallybio is a clinical-stage biotechnology company developing therapeutic candidates for severe, rare diseases driven by complement dysregulation and blood disorders. Its lead program, RLYB116, is a C5 inhibitor targeting immune platelet transfusion refractoriness and refractory antiphospholipid syndrome. The company's pipeline also includes RLYB332, a long-acting antibody in preclinical development for iron overload disorders.